NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. At the end of 2025, the company has two products in clinical development (NFL-101 and NFL-102) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol addiction).

Employees

Sector

Biotechnology & Medical Research

Calendar

04:40pm Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
21/10/26	€0.5500	-1.79%	27,063
20/10/26	€0.5600	-3.28%	23,137
19/10/26	€0.5790	+2.12%	18,414
16/10/26	€0.5670	-1.90%	27,495
15/10/26	€0.5780	-0.86%	36,369

Real-time Euronext Paris

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - NFL Biosciences

Company calendar

Market Closed - Euronext Paris 16:55:00 21/10/2026 BST			5-day change	1st Jan Change
0.5500 ^EUR	-1.79%		-5.66%	-53.31%

10-19	This week's earnings calendar: CAC stocks, Meta, Tesla, SAP and Nestlé in the spotlight
10-06	NFL Biosciences Provides Progress Update on NFL-101 and NFL-102 Clinical Programs in Smoking Cessation	CI

Market Cap	6.97M 7.82M 6.45M 5.84M 11M 738M 11.13M 77.37M 30.36M 388M 29.34M 28.73M 1.24B	P/E 2024	-9.56x	P/E 2025	-4.62x
Enterprise Value	5.35M 6M 4.95M 4.48M 8.45M 567M 8.55M 59.39M 23.3M 298M 22.52M 22.05M 949M	EV / Sales 2024	370,592x	EV / Sales 2025	70,790x
Free-Float	85.79%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Euronext Paris	ALNFL	Real-time
Deutsche Boerse AG	82F	Delayed
Börse Stuttgart	82F	Delayed

10-19	This week's earnings calendar: CAC stocks, Meta, Tesla, SAP and Nestlé in the spotlight
10-06	NFL Biosciences Provides Progress Update on NFL-101 and NFL-102 Clinical Programs in Smoking Cessation	CI
07-28	NFL Biosciences Submits Application For Authorization Of The Phase 2 Tonic Clinical Trial Evaluating NFL-102 In Smoking Cessation	CI
07-07	Nfl Biosciences Presents Three Scientific Communications on Nfl-101 and Nfl-102 At 2026 Srnt-Europe Conference	CI
06-30	NFL Biosciences Successfully Manufactures GMP Clinical Batch Of NFL-102 And Validates Industrial Production Chain	CI
06-30	NFL Biosciences validates industrial-scale production of NFL-102 for smoking cessation
06-01	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	CI
06-01	NFL Biosciences validates breakthrough in personalized medicine
05-26	Glimmers of hope for Middle East peace grow brighter
05-26	NFL Biosciences to File Patent Application for Smoking Cessation Drug-linked Biomarker	MT
05-25	NFL Biosciences files new patent application
05-25	NFL Biosciences Files Patent Application Protecting Predictive Efficacy Biomarker Associated With NFL-101	CI
05-11	NFL Biosciences SA Clarifies Objectives And Evaluation Criteria For Predictive Biomarker Associated With NFL-101	CI

NFL Biosciences Share Price

Stocks

ALNFL

FR0014003XT0

Biotechnology & Medical Research

Valuation: NFL Biosciences

Chart: NFL Biosciences

Latest news: NFL Biosciences

Analysts' recommendations: NFL Biosciences

Press Releases: NFL Biosciences

News in other languages: NFL Biosciences

Quotes and Performance

Price Extremes

Managers and Directors: NFL Biosciences

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

20/10/25	Nfl Biosciences Outlines Its Development Plan for Nfl-101 in Smoking Cessation Following Receipt of Scientific Advice from Several European Agencies and the U.S. Fda	CI
02/10/24	NFL Biosciences: Invest Securities reduces its target
15/07/24	NFL Biosciences: Invest Securities raises its target

10-06	NFL Biosciences: Progress Update Ahead of Upcoming Value-Creating Milestones for Its Two Clinical Programs in Smoking Cessation	BU
09-08	NFL Biosciences to Present Its Personalized Medicine Approach to Smoking Cessation at the 20th Congress of the Société Francophone de Tabacologie	BU
07-28	NFL Biosciences Submits an Application for Authorization of the Phase 2 TONIC Clinical Trial Evaluating NFL-102 in Smoking Cessation	BU
07-07	International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral Presentation on NFL-102	BU
06-30	NFL Biosciences Announces the Successful Manufacturing of a GMP Clinical Batch of NFL-102 and Validates Its Industrial Production Chain	BU

10-21	Agenda Zonebourse des résultats de sociétés : le 22 octobre 2026
10-19	Agenda Zonebourse des résultats de sociétés : semaine du 19 au 23 octobre 2026
10-17	Agenda des résultats de la semaine : valeurs du CAC, Meta, Tesla, SAP et Nestlé en piste
10-16	Agenda Zonebourse des résultats de sociétés : semaine du 19 au 23 octobre 2026
10-06	NFL Biosciences : point d’étape en vue des prochains jalons créateurs de valeur pour ses deux programmes cliniques dans le sevrage tabagique

1 day	-1.79%
1 week	-5.66%
Current month	-20.29%
1 month	-24.76%
3 months	-34.91%
6 months	-48.21%
Current year	-53.31%

1 week	0.53	0.58
1 month	0.53	0.76
Current year	0.53	1.85
1 year	0.53	1.85
3 years	0.53	3.28
5 years	0.53	4
10 years	0.53	5

Manager	Title	Age	Since
Bruno Lafont CEO	Chief Executive Officer	-	16/10/2024
Guillaume Audema DFI	Director of Finance/CFO	-	31/12/2021
Yannick Plétan CTO	Chief Tech/Sci/R&D Officer	-	16/10/2024

Director	Title	Age	Since
Ignacio Faus CHM	Chairman	-	26/02/2023
Bruno Lafont CHM	Chairman	-	16/10/2024
Francis Ahner BRD	Director/Board Member	-	18/05/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NFL BIOSCIENCES	-1.79%	-5.66%	-52.17%	-50.81%	7.97M
WUXI APPTEC CO., LTD.	-0.21%	-6.36%	+49.00%	+74.13%	66.34B
LONZA GROUP AG	-0.22%	+6.53%	+11.68%	+87.32%	52.92B
ARGENX SE	+0.82%	+5.41%	+8.05%	+73.53%	54.82B
IQVIA HOLDINGS INC.	+3.28%	+5.58%	+26.51%	+50.05%	44.09B
BEONE MEDICINES AG	+0.51%	+9.95%	+22.40%	+133.92%	43.72B
REVOLUTION MEDICINES, INC.	-1.15%	+0.39%	+263.21%	+594.60%	42.13B
CELLTRION, INC.	+0.10%	+9.90%	+16.11%	+59.33%	33.96B
WUXI BIOLOGICS (CAYMAN) INC.	-1.30%	-0.68%	+37.15%	+7.16%	26.17B
GENMAB A/S	+0.69%	+5.60%	+36.60%	+26.94%	23.37B
Average	+0.07%	+3.70%	+41.85%	+105.62%	38.75B
Weighted average by Cap.	+0.32%	+4.54%	+51.41%	+127.77%

	2024	2025
Net sales	46 51.62 42.59 38.54 72.61 4.87K 73.47 510.62 200.36 2.56K 193.65 189.62 8.16K	188 210.98 174.06 157.52 296.76 19.91K 300.28 2.09K 818.86 10.46K 791.43 774.95 33.35K
Net income	-2.08M -2.34M -1.93M -1.74M -3.28M -220M -3.32M -23.1M -9.06M -116M -8.76M -8.58M -369M	-3.32M -3.72M -3.07M -2.78M -5.24M -351M -5.3M -36.83M -14.45M -185M -13.97M -13.68M -589M
Net Debt	-2.07M -2.33M -1.92M -1.74M -3.27M -219M -3.31M -23.01M -9.03M -115M -8.72M -8.54M -368M	-1.62M -1.82M -1.5M -1.36M -2.56M -171M -2.59M -17.98M -7.05M -90.14M -6.82M -6.68M -287M